In a recent interview with EPM Magazine, Pieter Vercruysse shares Tjoapack’s perspective on how the oral solid dosage (OSD) market is evolving and what this means for pharmaceutical packaging partners.

While tablets and capsules remain the backbone of global pharma manufacturing, expectations around packaging have shifted significantly. Packaging is no longer viewed as an isolated final step—it is increasingly seen as a strategic component that influences fulfilment speed, regulatory compliance, and overall supply chain resilience.

Pieter highlights several key developments shaping the OSD segment:

• Greater flexibility for small and specialised batches: The rise of personalised therapies and niche indications requires adaptable operational models that support both large-scale and patient-specific production runs.
• Automation and digital integration: Thoughtful automation reduces variability and strengthens quality assurance, while digital platforms enhance visibility, traceability, and cross-functional collaboration.
• Throughput without rigidity: Standardised core processes allow Tjoapack to balance efficiency with customisation, ensuring high-volume runs and smaller batches can coexist within the same operational framework.
• Post-pandemic supply chain resilience: Closer integration between manufacturing, packaging, and distribution—supported by a global footprint—helps customers mitigate risk and maintain continuity.
• Pragmatic sustainability: While material innovation continues to evolve, immediate gains are achieved through waste reduction, operational efficiency, and smarter logistics planning.

Pieter emphasises that the future of OSD packaging lies in focused expertise and integration. As pharmaceutical companies reassess outsourcing strategies, specialist packaging partners are increasingly valued for their ability to support complex regulatory environments while enhancing speed, reliability, and patient access.

Ultimately, OSD packaging is no longer just about protecting tablets and capsules—it is about enabling a more agile, resilient, and patient-centric pharmaceutical supply chain.

📖 Read the full interview in EPM Magazine.

‍